Compumedics (ASX:CMP) said the US Food and Drug Administration cleared the Falcon home sleep testing device to be marketed in the US, according to a Wednesday Australian bourse filing.
The device will complement the firm's Somfit technology platform. Initial sales of the platform in the last six months were around AU$1 million.
The firm is currently targeting to achieve between 10% and 30% of the addressable market over the next 24 months.
Compumedics reaffirmed its guidance for the current fiscal year of revenues of at least AU$55 million and earnings before interest, taxes, depreciation, and amortization of about AU$5 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。